Maja Šutić1, Antje Motzek2, Gordana Bubanović3, Matthias Linke2, Ivan Sabol1, Oliver Vugrek1, Petar Ozretić1, Luka Brčić3, Sven Seiwerth3, Željko Debeljak4,5, Antonija Jakovčević3, Zoran Janevski6, Dinko Stančić-Rokotov6, Andrea Vukić-Dugac7, Marko Jakopović7, Miroslav Samaržija7, Ulrich Zechner2, Jelena Knežević1. 1. Ruđer Bošković Institute, Division for Molecular Medicine, Zagreb, Croatia. 2. Institute for Human Genetics, Johannes Gutenberg-University Mainz, Mainz, Germany. 3. Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia. 4. Institute of Clinical Laboratory Diagnostics, University Hospital Osijek, Osijek, Croatia. 5. Faculty of Medicine, Department of Pharmacology, JJ Strossmayer University of Osijek, Osijek, Croatia. 6. Department of Thoracic Surgery Jordanovac, Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia. 7. Department for Respiratory Diseases, Clinic for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
Abstract
BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide, with 5-year overall survival less than 15%. Therefore, it is essential to find biomarkers for early detection and prognosis. Aberrant DNA methylation is a common feature of human cancers and its utility is already recognized in cancer management. The aim of this study was to explore the diagnostic and prognostic value of the promoter methylation status of the ASC/TMS1/PYCARD and MyD88 genes, key adaptor molecules in the activation of the innate immune response and apoptosis pathways. METHODS: A total of 50 non-small cell lung cancer (NSCLC) patients were enrolled in the study. Methylation of bisulphite converted DNA was quantified by pyrosequencing in fresh frozen malignant tissues and adjacent non-malignant tissues. Associations between methylation and lung function, tumor grade and overall survival were evaluated using receiver-operating characteristics (ROC) analysis and statistical tests of hypothesis. RESULTS: Methylation level of tested genes is generally low but significantly decreased in tumor tissues (ASC/TMS1/PYCARD, P<0.0001; MyD88, P<0.0002), which correlates with increased protein expression. Three CpG sites were identified as promising diagnostic marker candidates; CpG11 (-63 position) in ASC/TMS1/PYCARD and CpG1 (-253 position) and 2 (-265 position) in MyD88. The association study showed that the methylation status of the ASC/TMS1 CpG4 site (-34 position) in malignant and non-malignant tissues is associated with the overall survival (P=0.019) and the methylation status of CpG8 site (-92 position) is associated with TNM-stage (P=0.011). CONCLUSIONS: The methylation status of the ASC/TMS1/PYCARD and MyD88 promoters are promising prognostic biomarker candidates. However, presented results should be considered as a preliminary and should be confirmed on the larger number of the samples. 2019 Translational Lung Cancer Research. All rights reserved.
BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide, with 5-year overall survival less than 15%. Therefore, it is essential to find biomarkers for early detection and prognosis. Aberrant DNA methylation is a common feature of human cancers and its utility is already recognized in cancer management. The aim of this study was to explore the diagnostic and prognostic value of the promoter methylation status of the ASC/TMS1/PYCARD and MyD88 genes, key adaptor molecules in the activation of the innate immune response and apoptosis pathways. METHODS: A total of 50 non-small cell lung cancer (NSCLC) patients were enrolled in the study. Methylation of bisulphite converted DNA was quantified by pyrosequencing in fresh frozen malignant tissues and adjacent non-malignant tissues. Associations between methylation and lung function, tumor grade and overall survival were evaluated using receiver-operating characteristics (ROC) analysis and statistical tests of hypothesis. RESULTS: Methylation level of tested genes is generally low but significantly decreased in tumor tissues (ASC/TMS1/PYCARD, P<0.0001; MyD88, P<0.0002), which correlates with increased protein expression. Three CpG sites were identified as promising diagnostic marker candidates; CpG11 (-63 position) in ASC/TMS1/PYCARD and CpG1 (-253 position) and 2 (-265 position) in MyD88. The association study showed that the methylation status of the ASC/TMS1 CpG4 site (-34 position) in malignant and non-malignant tissues is associated with the overall survival (P=0.019) and the methylation status of CpG8 site (-92 position) is associated with TNM-stage (P=0.011). CONCLUSIONS: The methylation status of the ASC/TMS1/PYCARD and MyD88 promoters are promising prognostic biomarker candidates. However, presented results should be considered as a preliminary and should be confirmed on the larger number of the samples. 2019 Translational Lung Cancer Research. All rights reserved.
Authors: Winfried Barchet; Anne Krug; Marina Cella; Celeste Newby; Jens A A Fischer; Andrzej Dzionek; Andrew Pekosz; Marco Colonna Journal: Eur J Immunol Date: 2005-01 Impact factor: 5.532
Authors: Arvind Virmani; Asha Rathi; Shashank Heda; Kenji Sugio; Cheryl Lewis; Vijay Tonk; Takashi Takahashi; Jack A Roth; John D Minna; David M Euhus; Adi F Gazdar Journal: Int J Cancer Date: 2003-11-10 Impact factor: 7.396
Authors: Maja Šutić; Jurica Baranašić; Lana Kovač Bilić; Mario Bilić; Antonija Jakovčević; Luka Brčić; Sven Seiwerth; Marko Jakopović; Miroslav Samaržija; Ulrich Zechner; Jelena Knežević Journal: Diagn Pathol Date: 2021-02-26 Impact factor: 2.644